Infliximab UC (sub-acute Not 23/04/2008 No manifestations) Approved Pemetrexed (2nd line) Not 22/08/2007 No approved Fludarabine CLL Not 28/02/2007 No phosphate approved Bevacizumab Adv./metastatic TA118 Not 24/01/2007 No colorectal Ca approved Cetuximab Metastatic colorectal Not 24/01/2007 No Ca (2nd line) approved Fluorouracil Colorectal Ca Not 24/01/2007 No (metastatic) approved Paclitaxel Early breast Ca Not 27/09/2006 No approved Efalizumab Psoriasis Market 26/07/2006 No Authorisation withdrawn Drotrecogin alfa Sepsis terminated No Temsirolimus Mantle cell Terminated No lymphoma
Infliximab UC (sub-acute manifestations) Not Approved 23/04/2008 No Pemetrexed (2nd line) Not approved 22/08/2007 No Fludarabine phosphate CLL Not approved 28/02/2007 No Bevacizumab Adv./metastatic colorectal Ca TA118 Not approved 24/01/2007 No Cetuximab Metastatic colorectal Ca (2nd line) Not approved 24/01/2007 No Fluorouracil Colorectal Ca (metastatic) Not approved 24/01/2007 No Paclitaxel Early breast Ca Not approved 27/09/2006 No Efalizumab Psoriasis Market Authorisation withdrawn 26/07/2006 No Drotrecogin alfa Sepsis terminated No Temsirolimus Mantle cell lymphoma Terminated No
NICE-TA-Adherence-Check-list-September-2013-HAST.docx